Expression data from native ZAP-70+CD38+ vs. ZAP-70-CD38- CLL cells

B-cell chronic lymphocytic leukemia (B-CLL) is a heterogenous disease with a highly variable clinical course and analysis of ZAP-70 and CD38 expression on B-CLL cells allowed for identification of patients with good (ZAP-70-CD38-), intermediate (discordant expression of ZAP-70 and CD38) and poor (ZAP-70+CD38+) prognosis. In an attempt to identify a molecular basis that may underly this diverse clinical behaviour DNA microarray technology was employed to compare eight ZAP-70+CD38+ with eight ZAP-70-CD38- B-CLL cases. We used microarrays to detail the global programme of gene expression distinguising B-CLL from patient with good (samples 1 to 8) and poor prognosis (sample 9 to 16) and identified distinct classes of up- and down-regulated genes. Keywords: Disease progression To compare the transcriptosomes of good prognosis CLL cases (ZAP-70-CD38-) to poor prognosis cases (ZAP-70+CD38+), we purified CD19+ cells from peripheral blood samples by immunomagnetic isolation using MidiMacs, resulting in >95% purity of leukemic cells as detected by FACS analysis of CD19+CD5+ cells. The leukemic cells were freshly purified from untreated patients and RNA was directly isolated from fresh cells without further ex vivo treatment of the cells. Eight immunomagnetically purified peripheral blood derived ZAP-70+CD38+ CLL cases were compared with eight ZAP-70-CD38- B-CLL cases.

慢性B淋巴细胞白血病（B-cell chronic lymphocytic leukemia, B-CLL）是一类异质性疾病，临床病程差异显著。通过分析B-CLL细胞表面ZAP-70（ZAP-70）与CD38（CD38）的表达水平，可将患者划分为预后良好（ZAP-70-CD38-）、中等（ZAP-70与CD38表达不一致）及预后不良（ZAP-70+CD38+）三类。
为揭示该疾病临床表型多样性背后的分子机制，本研究采用DNA微阵列（DNA microarray）技术，对8例ZAP-70+CD38+与8例ZAP-70-CD38-的B-CLL病例开展对比分析。
本研究利用微阵列解析了全局基因表达谱，以区分预后良好组（样本1至8）与预后不良组（样本9至16）的B-CLL，并鉴定出多组显著上调及下调的差异表达基因。
关键词：疾病进展
为对比预后良好CLL病例（ZAP-70-CD38-）与预后不良病例（ZAP-70+CD38+）的转录组，本研究通过MidiMacs免疫磁珠分离法从外周血样本中纯化CD19+细胞，经CD19+CD5+细胞的流式细胞术（fluorescence-activated cell sorting, FACS）检测，白血病细胞纯度可达95%以上。
所有白血病细胞均取自未经治疗的患者，新鲜分离后直接提取RNA，未对细胞进行额外的体外处理。
本研究共对8例经免疫磁珠纯化的外周血来源ZAP-70+CD38+ CLL病例与8例ZAP-70-CD38- B-CLL病例进行了对比分析。